178 related articles for article (PubMed ID: 33126762)
1. Identification of Iminium Intermediates Generation in the Metabolism of Tepotinib Using LC-MS/MS: In Silico and Practical Approaches to Bioactivation Pathway Elucidation.
Abdelhameed AS; Attwa MW; Kadi AA
Molecules; 2020 Oct; 25(21):. PubMed ID: 33126762
[TBL] [Abstract][Full Text] [Related]
2.
Alsubi TA; Attwa MW; Bakheit AH; Darwish HW; Abuelizz HA; Kadi AA
RSC Adv; 2020 Jun; 10(38):22668-22683. PubMed ID: 35514564
[TBL] [Abstract][Full Text] [Related]
3. Investigation of Fenebrutinib Metabolism and Bioactivation Using MS
Alsibaee AM; Aljohar HI; Attwa MW; Abdelhameed AS; Kadi AA
Molecules; 2023 May; 28(10):. PubMed ID: 37241965
[TBL] [Abstract][Full Text] [Related]
4. Reactive intermediates formation and bioactivation pathways of spebrutinib revealed by LC-MS/MS:
Alsibaee AM; Aljohar HI; Attwa MW; Abdelhameed AS; Kadi AA
Heliyon; 2023 Jun; 9(6):e17058. PubMed ID: 37484253
[TBL] [Abstract][Full Text] [Related]
5. Phase I metabolic profiling and unexpected reactive metabolites in human liver microsome incubations of X-376 using LC-MS/MS: bioactivation pathway elucidation and
Attwa MW; Kadi AA; Abdelhameed AS
RSC Adv; 2020 Jan; 10(9):5412-5427. PubMed ID: 35498318
[TBL] [Abstract][Full Text] [Related]
6. Piperazine ring toxicity in three novel anti-breast cancer drugs: an in silico and in vitro metabolic bioactivation approach using olaparib as a case study.
Alsubi TA; Attwa MW; Darwish HW; Abuelizz HA; Kadi AA
Naunyn Schmiedebergs Arch Pharmacol; 2023 Jul; 396(7):1435-1450. PubMed ID: 36738368
[TBL] [Abstract][Full Text] [Related]
7. Characterization of Stable and Reactive Metabolites of the Anticancer Drug, Ensartinib, in Human Liver Microsomes Using LC-MS/MS: An in silico and Practical Bioactivation Approach.
Abdelhameed AS; Attwa MW; Kadi AA
Drug Des Devel Ther; 2020; 14():5259-5273. PubMed ID: 33299299
[TBL] [Abstract][Full Text] [Related]
8. Identification and characterization of
Al-Shakliah NS; Attwa MW; AlRabiah H; Kadi AA
Anal Methods; 2021 Jan; 13(3):399-410. PubMed ID: 33410830
[TBL] [Abstract][Full Text] [Related]
9. Identification of reactive intermediate formation and bioactivation pathways in Abemaciclib metabolism by LC-MS/MS:
Kadi AA; Darwish HW; Abuelizz HA; Alsubi TA; Attwa MW
R Soc Open Sci; 2019 Jan; 6(1):181714. PubMed ID: 30800400
[TBL] [Abstract][Full Text] [Related]
10. Identification and characterization of
Al-Shakliah NS; Attwa MW; Kadi AA; AlRabiah H
RSC Adv; 2020 Apr; 10(28):16231-16244. PubMed ID: 35498820
[TBL] [Abstract][Full Text] [Related]
11. Detection and characterization of olmutinib reactive metabolites by LC-MS/MS: Elucidation of bioactivation pathways.
Attwa MW; Kadi AA; Abdelhameed AS
J Sep Sci; 2020 Feb; 43(4):708-718. PubMed ID: 31788977
[TBL] [Abstract][Full Text] [Related]
12. Profiling of
Al-Shakliah NS; Kadi AA; Aljohar HI; AlRabiah H; Attwa MW
RSC Adv; 2022 Jul; 12(32):20991-21003. PubMed ID: 35919181
[TBL] [Abstract][Full Text] [Related]
13. Ion Trap LC/MS reveals the generation of reactive intermediates in acalabrutinib metabolism: phase I metabolic profiling and bioactivation pathways elucidation.
Alsibaee AM; Aljohar HI; Attwa MW; Abdelhameed AS; Kadi AA
RSC Adv; 2024 May; 14(23):16170-16193. PubMed ID: 38769961
[TBL] [Abstract][Full Text] [Related]
14. Sapitinib: reactive intermediates and bioactivation pathways characterized by LC-MS/MS.
Attwa MW; Kadi AA
RSC Adv; 2019 Oct; 9(57):32995-33006. PubMed ID: 35529145
[TBL] [Abstract][Full Text] [Related]
15. LC-ESI-MS/MS reveals the formation of reactive intermediates in brigatinib metabolism: elucidation of bioactivation pathways.
Kadi AA; Attwa MW; Darwish HW
RSC Adv; 2018 Jan; 8(3):1182-1190. PubMed ID: 35540908
[TBL] [Abstract][Full Text] [Related]
16. High resolution mass spectrometry-based methodologies for identification of Etravirine bioactivation to reactive metabolites: In vitro and in vivo approaches.
Godinho ALA; Martins IL; Nunes J; Charneira C; Grilo J; Silva DM; Pereira SA; Soto K; Oliveira MC; Marques MM; Jacob CC; Antunes AMM
Eur J Pharm Sci; 2018 Jul; 119():70-82. PubMed ID: 29592839
[TBL] [Abstract][Full Text] [Related]
17. Reactive intermediates and bioactivation pathways characterization of avitinib by LC-MS/MS: In vitro metabolic investigation.
Attwa MW; Kadi AA; Abdelhameed AS
J Pharm Biomed Anal; 2019 Feb; 164():659-667. PubMed ID: 30472584
[TBL] [Abstract][Full Text] [Related]
18. Metabolic Stability Assessment of New PARP Inhibitor Talazoparib Using Validated LC-MS/MS Methodology: In silico Metabolic Vulnerability and Toxicity Studies.
Attwa MW; Kadi AA; Abdelhameed AS; Alhazmi HA
Drug Des Devel Ther; 2020; 14():783-793. PubMed ID: 32158196
[TBL] [Abstract][Full Text] [Related]
19. Characterization of reactive intermediates formation in dacomitinib metabolism and bioactivation pathways elucidation by LC-MS/MS:
Attwa MW; Kadi AA; Abdelhameed AS
RSC Adv; 2018 Nov; 8(68):38733-38744. PubMed ID: 35558335
[TBL] [Abstract][Full Text] [Related]
20. Reactive intermediates in naquotinib metabolism identified by liquid chromatography-tandem mass spectrometry: phase I metabolic profiling.
Attwa MW; Kadi AA; AlRabiah H; Darwish HW
RSC Adv; 2019 Mar; 9(18):10211-10225. PubMed ID: 35520926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
